Navigation Links
Amgen Announces Final Results of Its Tender Offer

THOUSAND OAKS, Calif., Dec. 14, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011.

Amgen has accepted for purchase 83,333,333 shares of its common stock at a price of $60.00 per share, for an aggregate cost of approximately $5 billion, excluding fees and expenses relating to the tender offer. These shares represent approximately 9.5 percent of the shares outstanding. The tender offer was oversubscribed and pursuant to the terms of the tender offer, shares will be accepted on a pro rata basis, except for tenders of odd lots, which will be accepted in full. Amgen has been informed by the depositary that the proration factor for the tender offer is approximately 87.79 percent.

BofA Merrill Lynch and Credit Suisse acted as dealer managers for the tender offer.  Stockholders who have questions or would like additional information about the tender offer may contact the information agent for the tender offer, Georgeson Inc. toll-free at (877) 278-9672.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2010, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.  Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)


Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen Announces Preliminary Results of Its Tender Offer
2. AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen.
3. Amgen Statement on European Investor Visit
4. S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.
5. Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
6. Amgen Announces Webcast of 2011 Third Quarter Financial Results
7. Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
8. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Amgen to Present at the Morgan Stanley Global Healthcare Conference
10. Amgen to Present at the Baird Healthcare Conference
11. Amgen to Present at the Stifel Nicolaus Healthcare Conference
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... Board of Directors has declared a special 1 percent stock ... is payable December 14, 2015, to shareholders of record December ... of additional shares of common stock. ... is a strong endorsement of our confidence in Ascendant,s growth ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of ... taking place in Chicago on Nov-29 th ... --> st  Scientific Assembly and Annual Meeting of the Radiological ... in Chicago on Nov-29 th through ... Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT ...
(Date:11/24/2015)... November 24, 2015 --> ... Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... to grow at the fastest rates? This visiongain ... data, trends, opportunities and prospects there. ,  ,Our 199-page ... most lucrative areas in the industry and the future ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... All her life, Don Peck’s mother wondered if she was ... she might have been. After a 25-year search for information, Don and his aunt ... shared a last name. Turns out, it was Don’s father who was descended from ...
(Date:11/24/2015)... Pass, OR (PRWEB) , ... November 24, 2015 , ... ... Lose too much body water to perspiration in the hot sun, and heat stroke ... to Fresh water advocate and radio host Sharon Kleyne. Every cell, system and structure ...
(Date:11/24/2015)... ... 2015 , ... The OSHA Training Center at Chabot-Las ... in Northern California, is calling on retail employers to implement safety measures to ... volume of sales and shoppers rapidly expands, retailers are strongly encouraged to develop ...
(Date:11/24/2015)... Miami, Fl (PRWEB) , ... November 24, 2015 , ... ... Farms. Adding houseplants is an easy and affordable way to bring long-lasting style and ... “green heroes” also provide oxygen, clean the air and keep on giving all year ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Take the audience on a journey with ... 3D camera path through a cloud of images without ever setting a single keyframe in ... the Inspector Window. Then use the controls to change the angle and depth of field ...
Breaking Medicine News(10 mins):